TAG:
pharmacogenomics
Pharmacogenomics is the study of how genes affect a person’s response to drugs. This relatively new field combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to develop effective, safe medications and doses that will be tailored to a person’s genetic makeup. Medical professionals and administrators hope this will save lives while also enhancing the practice of personalized medicine, in which drugs and drug combinations are optimized for each individual’s unique genetic makeup.
Many drugs that are currently available are “one size fits all,” but they don’t work the same way for everyone. Whether used to explain a patient’s response or lack thereof to a treatment, or act as a predictive tool, personalized medicine hopes to achieve better treatment outcomes, greater efficacy, minimization of the occurrence of drug toxicities and adverse drug reactions (ADRs). Adverse drug reactions are a significant cause of hospitalizations and deaths in the United States.
With the knowledge gained from the Human Genome Project, researchers are learning how inherited differences in genes affect the body’s response to medications. These genetic differences will be used to predict whether a medication will be effective for a particular person and to help prevent adverse drug reactions.
The field of pharmacogenomics is still in its infancy. Its use is currently quite limited, but new approaches are under study in clinical trials. In the future, pharmacogenomics will allow the development of tailored drugs to treat a wide range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.
The term pharmacogenomics is often used interchangeably with pharmacogenetics. Although both terms relate to drug response based on genetic influences, pharmacogenetics focuses on single drug-gene interactions, while pharmacogenomics encompasses a more genome-wide association approach, incorporating genomics and epigenetics while dealing with the effects of multiple genes on drug response.
2003’s Big Lab Stories Reflect Health Trends
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
“Companion Diagnostics” Enter Lab Marketplace
CEO SUMMARY: Although the field of pharmacogenomics is still in its infancy, it has begun to develop sub-specialty areas. “Companion diagnostics” describes the marriage of a therapeutic drug with a specific diagnostic assay that can identify which patients will benefit from a prescrip…
New Market Channel For Esoteric Testing
CEO SUMMARY: It’s a new marketing model for specialty esoteric tests that presents both clinical and financial challenges to hospital and health system laboratories. Niche labs offering esoteric tests are sending sales reps directly to physicians and bypassing pathologists and lab direc…
Laboratories Sit Squarely Between New Genetics and Today’s Medicine
“Clinical laboratories and pathology groups are at the leading edge of the genetic revolution.” —Rick J. Carlson. CEO SUMMARY: Healthcare futurist Rick J. Carlson believes that knowledge of the human genome will trigger revolutionary…
Quest Diagnostics, CVS Pharmacies, Premier, Novation, Luminex, Careside.
QUEST DOES DEAL WITH CVS DRUGSTORES FOR LAB TESTING PATHOLOGISTS CONCERNED about pharmacists moving into the lab testing arena should closely watch the newly-announced relationship between Quest Diagnostics Incorporated and CVS Corporation. Starting this m…
“March 11, 2002 Intelligence: Late Breaking Lab News”
Down in Orlando, Florida, Cognescenti Health Institute, now opening a newly-constructed clinical laboratory, has selected LabDat, Inc. to provide browser-based lab test ordering and results reporting. In response to the anticipated changes caused by genomic and prot…
DIANON Systems, United Health, Aetna, Quest Diagnostics, Orchid, AmeriPath
DIANON SYSTEMS INKS NATIONAL AGREEMENT WITH UNITEDHEALTHCARE A NEW NATIONAL AGREEMENT between DIANON Systems, Inc. and UnitedHealthcare was announced last week. The agreement allows DIANON Systems to provide pathology and genetic testing services to all the…
2001’s Ten Big Stories Presage Future Direction
CEO SUMMARY: During 2001, few labs found themselves under intense pressure to change or react to dramatic events in the healthcare marketplace. Like 2000, this past year was marked by evolutionary progress, not revolutionary change. However, continuing signs indicate that consumers will p…
Tripath Imaging Ready To Roil Pap Test Market
CEO SUMMARY: Single-handedly, Cytyc Corporation has built the market for thin-layer Pap smear testing. Executives at TriPath Imaging are now ready to challenge Cytyc’s dominance by offering what they believe is a different value proposition to labs: an automated liquid preparation syste…
Sunquest, Towers Perrin, Aetna, Quest Diagnostics, Roche Diagnostics, Careside
SUNQUEST REAFFIRMS LONG-TERM COMMITMENT TO COPATHPLUS PRODUCT EXPECT A FASCINATING competitive battle in the market for anatomic pathology software now that Cerner Corporation is acquiring Dynamic Healthcare Technologies, Inc. (DHT) DHT is the developer an…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.